NewEdge Advisors’s Insys Therapeutics, Inc. INSY Stock Holding History

NewEdge Advisors’s Portfolio INSY Stock Details INSY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-200	Closed	-$2.67K	–	1291
2017 Q2	$2.67K	Buy	+200	New	+$2.37K	﹤0.01%	1263

Other funds holding INSY

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $299B AUM 28.69% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

FHAM

Folger Hill Asset Management New York $16.5M AUM 19.96% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

NewEdge Advisors's INSY Position: Q3 2017 in Review

NewEdge Advisors sold out of Insys Therapeutics, Inc. (INSY) in Q3 2017, closing a stake of 200 shares — an estimated $2.67K sold.

NewEdge Advisors first reported a position in INSY in Q2 2017 and held it in 1 quarter. The position peaked at $2.67K in Q2 2017. 116 funds tracked by Wall St. Rank hold INSY as of Q3 2017.

NewEdge Advisors reported no remaining Insys Therapeutics, Inc. position as of Q3 2017 after selling out during the quarter.
NewEdge Advisors sold 200 Insys Therapeutics, Inc. shares in Q3 2017, an estimated $2.67K.
NewEdge Advisors first reported a position in Insys Therapeutics, Inc. in Q2 2017 and held it in 1 quarter.
NewEdge Advisors's Insys Therapeutics, Inc. position peaked at $2.67K in Q2 2017.
116 funds tracked by Wall St. Rank held Insys Therapeutics, Inc. as of Q3 2017.

Based on NewEdge Advisors's 13F filing for Q3 2017, filed 13 Nov 2017.